417 related articles for article (PubMed ID: 10077975)
1. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
Matsubara K
Nihon Hoigaku Zasshi; 1998 Oct; 52(5):301-5. PubMed ID: 10077975
[TBL] [Abstract][Full Text] [Related]
2. N-methyltetrahydro-beta-carboline analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin are oxidized to neurotoxic beta-carbolinium cations by heme peroxidases.
Herraiz T; Guillén H; Galisteo J
Biochem Biophys Res Commun; 2007 Apr; 356(1):118-23. PubMed ID: 17346675
[TBL] [Abstract][Full Text] [Related]
3. Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake.
Storch A; Hwang YI; Gearhart DA; Beach JW; Neafsey EJ; Collins MA; Schwarz J
J Neurochem; 2004 May; 89(3):685-94. PubMed ID: 15086525
[TBL] [Abstract][Full Text] [Related]
4. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
5. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
Shepherd KR; Lee ES; Schmued L; Jiao Y; Ali SF; Oriaku ET; Lamango NS; Soliman KF; Charlton CG
Pharmacol Biochem Behav; 2006 Mar; 83(3):349-59. PubMed ID: 16580056
[TBL] [Abstract][Full Text] [Related]
6. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.
Herraiz T; Guillén H; Arán VJ; Idle JR; Gonzalez FJ
Toxicol Appl Pharmacol; 2006 Nov; 216(3):387-98. PubMed ID: 16870220
[TBL] [Abstract][Full Text] [Related]
7. 2,9-Dimethyl-beta-carbolinium, a neurotoxin occurring in human brain, is a potent inducer of apoptosis as 1-methyl-4-phenylpyridinium.
Pavlovic S; Schulze G; Wernicke C; Bonnet R; Gille G; Badiali L; Kaminska A; Lorenc-Koci E; Ossowska K; Rommelspacher H
Neuroscience; 2006; 139(4):1525-37. PubMed ID: 16517085
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
Watanabe Y; Himeda T; Araki T
Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
10. MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact.
Lau YS; Novikova L; Roels C
Neurosci Res; 2005 Aug; 52(4):371-8. PubMed ID: 15936837
[TBL] [Abstract][Full Text] [Related]
11. A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
Kawasaki T; Ago Y; Kitao T; Nashida T; Takagi A; Takuma K; Matsuda T
Neuropharmacology; 2008 Oct; 55(5):654-60. PubMed ID: 18573265
[TBL] [Abstract][Full Text] [Related]
12. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.
Prediger RD; Rial D; Medeiros R; Figueiredo CP; Doty RL; Takahashi RN
Ann N Y Acad Sci; 2009 Jul; 1170():629-36. PubMed ID: 19686204
[TBL] [Abstract][Full Text] [Related]
13. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
14. [Contribution of MPTP to studies on the pathogenesis of Parkinson's disease].
Mizuno Y
Rinsho Shinkeigaku; 1989 Dec; 29(12):1494-6. PubMed ID: 2698296
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
Meuer K; Pitzer C; Teismann P; Krüger C; Göricke B; Laage R; Lingor P; Peters K; Schlachetzki JC; Kobayashi K; Dietz GP; Weber D; Ferger B; Schäbitz WR; Bach A; Schulz JB; Bähr M; Schneider A; Weishaupt JH
J Neurochem; 2006 May; 97(3):675-86. PubMed ID: 16573658
[TBL] [Abstract][Full Text] [Related]
16. Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice.
Knaryan VH; Samantaray S; Varghese M; Srinivasan A; Galoyan AA; Mohanakumar KP
Neuropeptides; 2006 Aug; 40(4):291-8. PubMed ID: 16712929
[TBL] [Abstract][Full Text] [Related]
17. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
[TBL] [Abstract][Full Text] [Related]
18. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
Lange KW
Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
20. MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice.
Viaggi C; Vaglini F; Pardini C; Caramelli A; Corsini GU
Neuropharmacology; 2009 Jun; 56(8):1075-81. PubMed ID: 19298832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
